Samsung Bioepis first acquires approval of Herceptin biosimilar in Europe

Samsung Bioepis(CEO/President Han-Seung Ko) has become the first to acquire sales approval of breast cancer biosimilar in Europe, away from other multinational pharmaceutical companies.

On the 20^th(local time), Samsung Bioepis announced that the company acquired the final sales approval of ‘Ontruzant(generic name: trastuzumab, project name: SB3),’ a anticancer biosimilar, from the European Com...